Market Access

Most Favored Nation drug pricing proposal aims to tie US medicine costs to lower European rates, but experts warn this approach could restrict patient access to lifesaving treatments, slow innovation, and jeopardize future drug development by importing flawed foreign price-control models.

The arrival of GLP-1 receptor agonists and dual agonists has delivered unprecedented efficacy, reframed obesity as a chronic disease, and sparked an industry gold rush.

The HOSP Alliance leader discusses the role of specialty pharmacies in the current market.

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.

Useful tips and parallels for staying in the game following a complete response letter.

Key areas may offer useful strategies for introducing innovative products to market.

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for broader coverage and policy solutions.

Pushing for access wins in quickly evolving market and digital health landscapes.

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

Webinar Date/Time: Mon, Jul 28, 2025 11:00 AM EDT

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial launch and patient administration is complex and lined with challenges that can impact product success and access.

Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in implementation, the potential unintended consequences, and how these actions could spark the shift to outcomes-based contracting in healthcare.

Not lost in the mix of June's wide-ranging coverage in Pharmaceutical Executive is an honest take on what guest thought leaders argue is “undoubtedly” the hardest job in biopharma.

Special Guest Opinion: A reimagined regulatory framework for the life sciences is not just pro-investor—it is pro-patient.

These diseases require specialty treatment typically unavailable at local retail pharmacies or small health systems, making it extremely difficult for many patients to get the care they need.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good practice, it is a strategic imperative.

Heparin is a critical drug that is highly dependent on the global supply chain and is derived from a highly complex process.

Demand for semaglutide and other GLP-1s is expected to grow exponentially over the next 3–5 years.

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy.

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions.

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

Navigating technology and regulatory shifts in pharma revenue management.

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The argument for weighing clinical points more heavily in the access equation.

A seminar shares key observations and learnings from the first round of direct price negotiations.